Organoid-Guided Precision: Advancing Indication Selection in ADC Development
- Physiologically relevant screening platform: Patient-derived organoids (PDOs) retain tumor complexity, offering more predictive ADC response than 2D or animal models
- Integrated target validation and cytotoxicity assessment: Concurrently evaluate antigen expression and ADC potency across cancer types
- Biomarker-driven patient stratification: Link PDOs response with molecular data to identify predictive markers and guide patient selection